Bli medlem
Bli medlem

Du är här

2016-05-11

Santhera Pharmaceuticals Holding AG: Santhera's Shareholders Approve all Board Proposals at Annual Shareholders' Meeting

Santhera Pharmaceuticals Holding AG / Santhera's Shareholders Approve all
Board Proposals at Annual Shareholders'Meeting . Processed and transmitted by
NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
Liestal, Switzerland, May 11, 2016 - Santhera Pharmaceuticals (SIX: SANN)
announces that a large majority of shareholders approved all proposals by the
Board of Directors at the Annual Shareholders' Meeting (ASM) today.
Participating shareholders represented a total of 3'211'953 shares or 51.2%
of the share capital with voting power.

"The results of today's ASM are a strong vote of confidence in our strategy
and achievements and I thank our shareholders for their consent and support,"
saidMartin Gertsch
, Chairman of the Board of Directors. "Indeed, 2015 was an exceptionally
successful year for Santhera with many milestones. After the European
Commission granted marketing approval for Raxone®for the treatment of Leber's
hereditary optic neuropathy (LHON), we are at present advancing the
commercial roll-out across Europe. The regulatory filing for the second
indication Duchenne muscular dystrophy (DMD) in Europe will follow very soon
and we have now requested a meeting with the FDA to discuss the filing also
in the US. Financially, we closed 2015 with a positive result and our strong
cash position from successful financings allows us to advance our development
programs and support our transition to a fully integrated specialty
pharmaceutical company.

Approval of the 2015 Annual Report, result appropriation and reallocation of
reserves

The shareholders endorsed the Annual Report, the annual financial statements
and the consolidated financial statements for 2015, the appropriation of the
net result of CHF -2,963,843 to new account as well as the reallocation of
reserves from capital contribution to free reserves. Furthermore, the
shareholders granted discharge to the members of the Board of Directors and
Executive Management for the financial year 2015.

Improved capital structure supports strategic flexibility and expansion of the
organization

The shareholders approved the increase and extension of the authorized capital
and the increase of the conditional capital for employee participation. With
their consent, the shareholders strengthen the financial flexibility of the
Company, particularly in view of upcoming regulatory submissions, additional
clinical development efforts, continuation of commercial roll-out and the
related build-up and expansion of the organization with qualified staff.

Remuneration for Board of Directors and Executive Management approved

In a consultative vote, the shareholders endorsed the Compensation Report
2015. The shareholders consented to the total annual compensation amounts for
members of the Board of Directors up to the Annual Shareholder's Meeting
2017. For Executive Management, the shareholders approved the alignment of
the compensation period of the fixed compensation to the financial year of
the Company (January 1 to December 31) and gave their consent to the fixed
compensation for the financial years 2016 and 2017. Subsequently, they also
approved the change of the voting procedure on the variable compensation to a
retrospective approval which will apply first time for the business year
2016.

Re-election of members of the Board of Directors

Shareholders confirmed Martin Gertsch and Jürg Ambühl as members of the Board
of Directors and the Compensation Committee. Furthermore, Martin Gertsch was
re-elected as Chairman of the Board for another term of one year.
Shareholders also supported the appointment of Ernst&Young Ltd. as auditors
for the financial year 2016 and elected Dr. Balthasar Settelen, Basel, as
independent proxy until the close of the Annual Shareholders' Meeting 2017.

Details on the agenda items

The proposals and explanations about the agenda items are available on the
Company's website atInvestors and Media/Investor toolbox/Shareholder Meetings

. From end of this week, the protocol of the Annual Shareholder's Meeting will
also be available.

New website

Santhera has today launched its new www.santhera.com website. The new website
has been de-signed to reflect the Company's business focus and market
strategies and supports the positioning of Santhera as a leader in developing
medicines to meet the needs of patients living with mitochondrial disorders
and other rare diseases.

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical
company focused on the development and commercialization of innovative
pharmaceutical products for the treatment of orphan mitochondrial and
neuromuscular diseases. Santhera's lead product Raxone®is authorized in the
European Union for the treatment of Leber's hereditary optic neuropathy
(LHON). Santhera develops Raxone®in two additional indications, Duchenne
muscular dystrophy (DMD) and primary progressive multiple sclerosis (PPMS),
and omigapil for congenital muscular dystrophy (CMD), all areas of high unmet
medical need. For further information, please visit the Company's
websitewww.santhera.com.

Raxone®and Catena®are trademarks of Santhera Pharmaceuticals.

For further information, contact:

Thomas Meier, PhD, Chief Executive Officer Christoph Rentsch, Chief
Financial Officer
Phone +41 61 906 89 64 Phone +41 61 906
89 65
thomas.meier@santhera.com
christoph.rentsch@santhera.com

US investor contact
US Public Relations contact

Hans Vitzthum, LifeSci Advisors, LLC Deanne Eagle, Planet
Communications
Phone +1 212 915 2568 Phone +1 917 837
5866
hans@lifesciadvisors.com
deanne@planetcommunications.nyc

Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of the Company to be
materially different from those expressed or implied by such statements.
Readers should therefore not place undue reliance on these statements,
particularly not in connection with any contract or investment decision. The
Company disclaims any obligation to update these forward-looking statements.

# # #

News release Annual Shareholder Meeting 2016
http://hugin.info/137261/R/2011706/744911.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Globenewswire

HUG#2011706

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.